Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis
Main Authors: | BMY Cheung, Y Fei, MF Tsoi |
---|---|
Format: | Article |
Language: | English |
Published: |
Radcliffe Medical Media
2020-05-01
|
Series: | European Cardiology Review |
Online Access: | https://www.ecrjournal.com/articleindex/ecr.2020.15.1.PO17 |
Similar Items
-
Posters from the 24th Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy
by: BMY Cheung, et al.
Published: (2020-05-01) -
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
by: Chris Wai Hang Lo, et al.
Published: (2021-03-01) -
Pharmacogenetics of new classes of antidiabetic drugs
by: Selma Imamovic Kadric, et al.
Published: (2021-12-01) -
Blood Lead Level and Hypertension Risk in the United States National Health Nutrition and Examination Survey (NHANES) 1999–2016
by: BMY Cheung, et al.
Published: (2020-05-01) -
Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.
by: Gyeongsil Lee, et al.
Published: (2017-01-01)